City of Hope licenses ProBioGen cell line for COVID-19 vaccine candidate

9 June 2021
probiogen-big

German contract development and manufacturing company ProBioGen has entered a commercial product license agreement with City of Hope, an independent research and treatment center for cancer, diabetes and other life-threatening diseases, granting the rights to use ProBioGen's cell line AGE1.CR.pIX® for manufacturing City of Hope's COVID-19 vaccine candidate.

ProBioGen's innovative vaccine development platform is expected to be ideally suited for the production of large quantities of City of Hope's synthetic MVA-based COVID-19 vaccine. It will enable City of Hope and/or its commercial partners to manufacture the vaccine at scale for late-stage clinical development and eventually, the market to address the urgent needs of the ongoing pandemic.

The vaccine is currently being tested in a Phase I clinical trial, and was manufactured on City of Hope's main campus within its Center for Biomedicine & Genetics, one of its three manufacturing facilities that meet strict GMP (good manufacturing practice) guidelines.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology